Objective To investigate the efficacy and safety of liposomal amphotericin B(L-AmB)for the salvage treatment of invasive fungal disease(IFD)in patients with hematological diseases.Methods Data were retrospectively collected from 80 patients with hematological issues treated with L-AmB between June 2023 and December 2023 after failure of previous antifungal therapy.Baseline patient information,clinical efficacy,and factors affecting the efficacy of L-AmB were analyzed by logistic regression.Moreover,adverse effects associated with L-AmB were evaluated.Results Among the 80 patients,9(11.2％)had proven IFD,43(53.8％)had probable IFD,and 28(35.0％)had possible IFD.The efficacy rate of L-AmB salvage therapy for IFD was 77.5％,with a median daily dose of 3(range:1-5)mg·kg-1·d-1 and a median dosing course of 14(range:8-25)days.Multivariate logistic regression analysis showed that the disease remission status(OR=4.337,95％CI 1.167-16.122,P=0.029)and duration of medication(OR=1.127,95％CI 1.029-1.234,P=0.010)were independent factors affecting the efficacy of L-AmB.The incidence of infusion reactions associated with L-AmB,including fever and chills,was 5.0％.The incidence of hypokalemia was 28.8％(predominantly grades 1-2),and the incidence of nephrotoxicity was 11.3％(predominantly grades 1-2).Conclusion L-AmB is safe and effective in the treatment of patients with IFD who are intolerant to or who have experienced no effect of previous antifungal therapy,with a low rate of adverse reactions.
维普
万方数据